eureKING, the first European SPAC in healthcare focused on bioproduction, today announced that it has submitted a firm offer for an exclusive period to evaluate the acquisition Skyepharma, a 27-year-old French company engaged in drug development.
The SPAC raised €150 million (about US $164 million) in May 2022 and lists on the Euronext Paris.
BNP Paribas and Société Générale Corporate & Investment Banking are financial advisors to eureKING and Willkie Farr & Gallagher and Linklaters are legal advisors to eureKING.
Claris Avocats is legal advisor to Skyepharma.
.
